Correction: FDA Office Of Women’s Health
This article was originally published in The Pink Sheet Daily
The first major undertaking for new FDA Assistant Commissioner for Science Linda Tollefson under her duties as head of FDA's Office of Women's Health is likely to be responding to the agency's decision on the over-the-counter switch application for Barr's Plan B contraceptive
You may also be interested in...
Former Center for Veterinary Medicine Deputy Director Linda Tollefson will oversee FDA's Offices of Women's Health and Orphan Products Development.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.